Clinical Trials Browser

Phase 1 × Carcinoma, Hepatocellular × spartalizumab × Clear all

NCT06364787 2024-04-15

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Phase 1 Not yet recruiting

18 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1 Terminated

61 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02988440 2020-12-19

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Phase 1 Completed

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms